Emad Jafarzadeh

Dr. Emad Jafarzadeh


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2023 in Acta Histochemica
Verified
Journal Article
Closed access
SKSepideh KarkonShayan
Sepideh KarkonShayan
HAHasan Aliashrafzadeh
Hasan Aliashrafzadeh
HDHassan Dianat-Moghadam
Hassan Dianat-Moghadam
NRNima Rastegar-Pouyani
Nima Rastegar-Pouyani
MMMohammadreza Majidi
Mohammadreza Majidi
EJEmad Jafarzadeh
Emad Jafarzadeh

17 April 2024 in Translational Oncology
Verified
Journal Article
Open access
FJFereshtehsadat Jalali
Fereshtehsadat Jalali
FFFatemeh Fakhari
Fatemeh Fakhari
ASAfrah Sepehr
Afrah Sepehr
JZJaber Zafari
Jaber Zafari
BSBehnam Omidi Sarajar
Behnam Omidi Sarajar
EJEmad Jafarzadeh
Emad Jafarzadeh
Doxorubicin (DOX) a chemotherapy drug often leads to the development of resistance, in cancer cells after prolonged treatment. Recent studies have suggested that using metformin plus doxorubicin could result in synergic effects. This study focuses on exploring the co-treat treatment of doxorubicin and metformin for various cancers. Following the PRISMA guidelines we conducted a literature search using different databases such as Embase, Scopus, Web of Sciences, PubMed, Science Direct and Google Scholar until July 2023. We selected search terms based on the objectives of this study. After screening a total of 30 articles were included. The combination of doxorubicin and metformin demonstrated robust anticancer effects, surpassing the outcomes of monotherapy drug treatment. In vitro experiments consistently demonstrated inhibition of cancer cell growth and increased rates of cell death. Animal studies confirmed substantial reductions in tumor growth and improved survival rates, emphasizing the synergistic impact of the combined therapy. The research' discoveries collectively emphasize the capability of the co-treat doxorubicin-metformin as a compelling approach in cancer treatment, highlighting its potential to address medicate resistance and upgrade generally helpful results. The findings of this study show that the combined treatment regimen including doxorubicin and metformin has significant promise in fighting cancer. The observed synergistic effects suggest that this combination therapy could be valuable, in a setting. This study highlights the need for clinical research to validate and enhance the application of the doxorubicin metformin regimen.

19 May 2025 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
EJEmad Jafarzadeh
Emad Jafarzadeh
VMVahideh Montazeri
Vahideh Montazeri
SAShima Aliebrahimi
Shima Aliebrahimi
ASAhmad Habibian Sezavar
Ahmad Habibian Sezavar
MGMohammad H. Ghahremani
Mohammad H. Ghahremani
SOSeyed Nasser Ostad
Seyed Nasser Ostad
Ovarian cancer (OC) remains a leading cause of gynaecological cancer deaths due to late diagnosis and the emergence of resistance to platinum‐based chemotherapy, like cisplatin (Cis). Here, we investigated the potential of metformin (Met), a drug commonly used for type 2 diabetes, to overcome Cis resistance in OC. Our findings revealed a synergistic effect of Met with Cis in inhibiting cell viability, proliferation and colony/sphere formation capacity in both cisplatin‐sensitive (A2780) and ‐resistant (A2780/CDDP) ovarian cancer cell lines. This synergistic action triggered apoptosis through DNA damage, S‐phase cell cycle arrest and modulation of autophagy. Met also significantly decreased the expression of pluripotency transcription factors (Oct‐4, Sox2 and Nanog), indicating its potential to target cancer stem cells (CSCs). Furthermore, the combination therapy downregulated multidrug resistance protein 1 (MDR1) and excision repair cross‐complementation group 1 (ERCC1) expression, thereby sensitising resistant cells to Cis‐induced cytotoxicity. Additionally, the combination treatment suppressed the Hedgehog (Hh) signalling pathway, which is an important factor in inhibiting CSCs. Our study highlights the potential of the Met signalling pathway to synergise with Cis, overcoming therapeutic resistance in OC by targeting diverse cellular processes, including CSCs, and warrants further investigation in preclinical models.

25 November 2024 in Critical Reviews in Toxicology
Verified
Journal Article
Closed access
ASAhmad Habibian Sezavar
Ahmad Habibian Sezavar
NRNima Rastegar-Pouyani
Nima Rastegar-Pouyani
NKNader Rahimi Kakavandi
Nader Rahimi Kakavandi
FFFatemeh Fakhari
Fatemeh Fakhari
EJEmad Jafarzadeh
Emad Jafarzadeh
SOSeyed Nasser Ostad
Seyed Nasser Ostad
Per- and polyfluoroalkyl substances (PFAS) are synthetic chemicals used widely in industrial and commercial applications. Concerns exist about their potential link to cancer risk as possible endocrine-disrupting chemicals. We conducted a meta-analysis to evaluate the dose-response relationship between PFAS, perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), perfluorodecanoic acid (PFDA), perfluorohexanesulfonic acid (PFHxS) exposure and risk of breast, prostate, colorectal, and ovarian cancers. We systematically searched major databases through May 2022 and identified 13 observational studies for inclusion. Using random-effects models, we calculated summary odds ratios (ORs) and 95% confidence intervals (CIs) comparing the highest versus lowest PFAS exposure categories. Additionally, we analyzed the dose-response correlation between PFAS and cancer risk in a subset of studies. The study revealed no substantial correlation between exposure to PFASs and the incidence of breast cancer (BC) (ORPFOS = 1.15, 95% CI = 0.91-1.46, ORPFOA = 1.01, 95% CI = 0.68-1.50, ORPFNA = 0.88, 95% CI = 0.64-1.21, ORPFHxS = 1.22, 95% CI = 0.40-3.77, and ORPFDA = 1.29, 95% CI = 0.41-4.10), ovarian cancer (ORPFOA = 1.43, 95% CI = 0.84-2.42), prostate cancer (ORPFOA = 1.05, 95% CI = 0.88-1.26), and colorectal cancer (ORPFOA = 0.77, 95% CI = 0.53-1.12) in the highest versus lowest exposure analysis. However, dose-response analysis showed that for every 1 ng/ml increase in PFNA and 2 ng/ml increase in PFOA, the relative risk for BC decreased significantly (RR 0.67, 95% CI 0.45-0.99 and RR 0.94, 95% CI 0.89-0.98, respectively). Non-linear dose-response analysis found no significant changes in BC risk with increasing PFAS levels. In conclusion, while the highest versus lowest analysis does not support associations between PFAS exposure and the risk of these cancers, linear dose-response analysis suggests potential inverse relationships between PFNA/PFOA levels and BC risk. Further research is warranted on these potential protective effects.

11 June 2025 in Translational Oncology
Verified
Journal Article
Open access
BSBehnam Omidi Sarajar
Behnam Omidi Sarajar
NRNima Rastegar-Pouyani
Nima Rastegar-Pouyani
ARAzadeh Rasouli
Azadeh Rasouli
FNFateme Nikbakht
Fateme Nikbakht
MMMahdieh Nezami Majd
Mahdieh Nezami Majd
MDMohsen Dehghani
Mohsen Dehghani
Several clinical trials have shown that combining metformin with paclitaxel-based chemotherapy has a promising effect on various tumors but with inconsistent findings. We conducted a systematic review and meta-analysis to compare the effects of paclitaxel plus metformin versus paclitaxel-based chemotherapy alone in different organ neoplasms. A comprehensive literature search was performed in Scopus, PubMed, Web of Sciences, Embase and also Google scholar until December 2023 using MeSH keywords and all similar terms limited to randomized controlled trials (RCTs). The retrieved studies were assessed for methodological quality. Pooled standardize mean difference (SMD), odds ratio (OR) and 95 % confidence intervals (CI) of clinical outcomes were calculated using random-effects meta-analysis. Of 921 records, ultimately, 14 RCTs met the criteria for inclusion in the meta-analysis. Based on a meta-analysis findings, combination therapy of a paclitaxel-based regimen with metformin was found to be significantly associated with improved overall survival (OS) compared to the paclitaxel alone in various types of cancers (pooled SMD: 1.27; 95 % CI: 0.10, 2.43). Moreover, the metformin plus paclitaxel showed a borderline significant improvement in the pathological complete response (pCR) rate compared to the paclitaxel alone (Pooled OR: 1.74; 95 % CI: 0.96, 3.15). However, there was no significant improvement in the metformin plus paclitaxel group compared to the paclitaxel group for progression-free survival (PFS) and disease-free survival (DFS). The findings indicate that a combination of paclitaxel-based chemotherapy with metformin enhances OS and pCR in cancer patients. This combination therapy has the potential to improve treatment effectiveness and safety.

1 November 2025 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
EJEmad Jafarzadeh
Emad Jafarzadeh
BSBehnam Omidi Sarajar
Behnam Omidi Sarajar
ALArmineh Rezaghol Lalani
Armineh Rezaghol Lalani
NRNima Rastegar-Pouyani
Nima Rastegar-Pouyani
SAShima Aliebrahimi
Shima Aliebrahimi
SOSeyed Nasser Ostad
Seyed Nasser Ostad
Introduction: The persistent drug resistance observed in lung cancer necessitates innovative strategies to improve therapeutic outcomes. This review investigates the potential of combining metformin (Met) and cisplatin (Cis) to overcome drug resistance and enhance treatment efficacy. Cis's limitations, including drug resistance and adverse effects, coupled with Met’s established safety profile, form the backdrop for this exploration. Methods: Systematic literature searches across major databases identified relevant studies exploring the synergistic effects of Met and Cis in the context of drug-resistant lung cancer. Data extraction encompassed diverse facets, including treatment protocols, cellular responses, and mechanistic insights. The synthesis of these findings sheds light on the potential of this combination therapy to combat drug resistance. Results: Numerous in vitro and in vivo studies have demonstrated the ability of the Met + Cis combination to sensitize drug-resistant lung cancer cells. The co-treatment consistently showed enhanced inhibition of cell proliferation, elevated apoptosis rates, and attenuated migration and invasion capabilities compared to monotherapies. Mechanistically, Met’s modulatory effect on key pathways, such as AMPK-mTOR and ROS-mediated signaling, appears to underlie its ability to counter drug resistance. Conclusion: The Met + Cis combination holds promise as an innovative strategy to counter drug resistance in lung cancer. By harnessing the synergistic effects of these agents, combination therapy offers a novel approach to enhance treatment efficacy and mitigate the challenges posed by drug-resistant lung cancer. Although further clinical validation is required, the Met + Cis synergy represents a promising avenue in the pursuit of improved lung cancer therapy outcomes.